mov19-bbz car t cells
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2018 (NCT03585764)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07116057 | Phase 1 | Oct 7, 2025 | National Cancer Institute (NCI), University of Pennsylvania |
| NCT03585764 | Phase 1 | Sep 30, 2018 | University of Pennsylvania |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Pennsylvania | Academic/Hospital | 2 | 2 | 1 | 2018 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1